

# Medicinal Chemistry 2

## Sulfonamides (Sulfa drugs)

Dr. Mamdouh Fawzy Ahmed  
Faculty of Pharmacy  
Sohag University

# Sulfonamides (Sulfa drugs)

## Antibiotics

### Definition

- 1942, Waksman “an antibiotic is a substance produced by microorganisms which has the capacity of inhibiting the growth & destroying other microorganisms”.
- Later “ any substance produced by a living organism that is capable of inhibiting the growth or survival of one or more species of microorganisms in low concs.
- medicinal chemists to modify the natural antibiotics to prepare new synthetic analogs so we now have *semisynthetic* & *synthetic* derivatives in the definition.


### Classification of Antibiotics

<b><math>\beta</math>-Lactam</b>	Penicillins & Cephalosporins
	Aminoglycoside: Streptomycin & Kanamycin
	Tetracyclines
<b>Non- <math>\beta</math>-Lactam</b>	Macrolides: Erythromycin & Oleandomycin
	Polypeptide: Polymixin
	Polyene: Amphotericin
	Miscellaneous : Chloramphenicol

# Sulfonamides (Sulfa drugs)

## Sulfa drugs


### Mechanisms of action of antibacterial drugs [5]



# Sulfonamides (Sulfa drugs)

## Bacterial Cell Wall

Human cells have **no cell wall**, but bacterial cells need a cell wall which composed of Peptidoglycan & Proteins. since they have a **hypotonic environment** in which the cell functions. If no cell wall, bacterial cells would rupture leading to cell death..




- ❖ These differences are the key for treatment of bacterial diseases by use of antibiotics.
- ❖ Without such differences it would be difficult to target and kill bacterial cells once they get into human body.

# Sulfonamides (Sulfa drugs)

## Discovery:

- ❖ In 1932: Domagk studied the antimicrobial effect of Prontosil Dye "brilliant red Dye" → it was found to be active ≠ Streptococcal infection in mice [in vivo] but inactive on bacterial culture [in vitro].




Prontosil Dye (prodrug)

# Sulfonamides (Sulfa drugs)

## Discovery:

- ❖ In 1935: Trefouel discovered the conversion of inactive **prontosil** dye -*in vivo*- into active **Sulfanilamide** "Lead cpd or Prototype". This finding was confirmed by isolating free sulfonamide from blood & urine of patients treated with Prontosil.




- ❖ Prontosil is inactive *in vitro* but *in vivo*  $\rightarrow$  sulfanilamide (active form) by reductive cleavage
- ❖ This led to discovery of the first synthetic antibacterial agent

# Sulfonamides (Sulfa drugs)

## Chemistry of sulfonamide



Chemistry of sulfonamide: they are classified as

Sulfa drugs

[1] <u>Aniline-substituted sulfonamide</u>	[2] <u>Prodrugs giving active sulfonamide</u>	[3] <u>Non-aniline sulfonamides</u>
$\text{H}_2\text{N}-\text{C}_6\text{H}_4-\text{SO}_2-\text{NH}-\text{R}$ <b>Sulfanilamides</b>	 <b>Sulfasalazine</b>	$\text{H}_2\text{N}-\text{C}_6\text{H}_4-\text{SO}_2-\text{NH}-\text{CO}-\text{CH}_3$ <b>Mafenide acetate</b>

# Sulfonamides (Sulfa drugs)


## M. O . A of sulfonamide:

- Sulphanilamides are active **BACTERIOSTATIC** [ so, eradication of m. o. is by normal immunity of body ].
- Many bacteria are impermeable to folic acid, so they rely on their ability to synthesize folate from PABA “P-AminoBenzoic Acid” , Pteridine & Glutamate ≠ MAMMALS who can't synthesize folic acid, so obtained from diet & so not affected by sulfonamides [selective chemotherapy].
- Because of their structural similarity to PABA ,Sulphonamides act as competitive reversible inhibitor with this substrate for the enzyme **DIHYDROPTEROATE SYNTHETASE** ,thus  synthesis of folic acid  thymidine, purine synthesis  synthesis of DNA  multiplication & growth of m.o.

# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:





### Biosynthesis of folate co-enzymes:



# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:

By using sulfonamides



# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:

This mechanism is supported by:

- ❖ 1. PABA added to culture media antagonizes effect of sulfonamides.
- ❖ 2. Man can't form folic acid  $\square$  so his cells are immune to sulfonamides.
- ❖ 3. M.O. which can utilize performed folic acid are less sulfonamides susceptible.

# Sulfonamides (Sulfa drugs)

## M. O . A of sulfonamide:

### Resistance of m.o. to sulfonamide drugs by:

- ❖ 1. The bacterial cell wall becomes more permeable to folic acid.
- ❖ 2. The m.o. learn to utilize preformed folic acid.
- ❖ 3. The organism develop alternate pathway for synthesis of folic acid.
- ❖ 4. increase PAPA synthesis by m.o. to overcome inhibition of dihydropteroate synthetase.

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship


N.B: As structure become more close to PABA  more active.

The 2 functional groups must be para that other positional isomers [m- or o-] are inactive.

Other substitution on benzene ring  
→ inactive

Other aromatic ring: decrease activity

Substitution of benzene ring with 5-membered ring cause inactivation.  
[due to different spacing between the two functional groups]



Free NH<sub>2</sub> group is **ESSENTIAL** for activity:

[1] If substituted by another group [as alkyl or alkoxy] → inactive  
But, if substituted by a group that will be converted to NH<sub>2</sub> group in vivo [as NO<sub>2</sub>, NO, N=N, NHCOR, NH-OH] → active


[2] Acylation of N with Dicarboxylic acid as succinic or phthalic acid, give sulfonamide NOT absorbed from small intestine BUT hydrolyzed in large intestine into free sulfonamide [Local Intestinal action]

If di-substituted [-SO<sub>2</sub>NR<sub>2</sub>] → Inactive  
If mono-substituted → ↑ activity

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA  more active.




### Change in A

- ❑ Free  $\text{NH}_2$  is essential for activity.
- ❑ Removal of  $\text{NH}_2 \rightarrow$  inactive compounds.
- ❑ Alkylation of  $\text{NH}_2 \rightarrow$  inactive compounds.
- ❑ Shifting  $\text{NH}_2$  gp to *m*- or *o*-position ► inactive compounds.
- ❑ Substitution with  $\text{NO}_2$ ,  $\text{NHOH}$ , azo or acetylation ► prodrugs which upon reduction or hydrolysis *in vivo* ► free  $\text{NH}_2$  (e.g. intestinal sulfa) still retain its activity.

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA  more active.




### Change in B

1. Phenyl group is essential: replacement with naphthalene, anthracene, pyridine or by another heterocyclic rings or saturation to cyclohexyl  $\rightarrow$  inactive compounds.
2. Substitution on benzene ring by halogen or any other group  $\blacktriangleright$  loss of activity.

# Sulfonamides (Sulfa drugs)

## Structure Activity Relationship

N.B: As structure become more close to PABA  more active.




### Change in C

1.  $\text{SO}_2$  must be **directly** attached to benzene ring.
2. R should be **electron withdrawing group**  $\blacktriangleright \uparrow$  acidity  $\blacktriangleright \downarrow pK_a \blacktriangleright \uparrow$  ionization  $\blacktriangleright \uparrow$  activity
3. N is best to be N-acyl “**prodrug**” this will help in;
  - Mask the **bitter taste** (can be used orally as syrup).
  - Hydrolyzed in **vivo** to give **free active** compound.

# Sulfonamides (Sulfa drugs)

## Physicochemical properties of sulfa drugs

[1] They are weak organic acids: due to  $\text{SO}_2\text{NH}_2$  group [by loss of proton & stabilization of -ve charge by resonance], & this determine pka of the drug.





N.B: acidity increases by attachment of e-withdrawing group to N4

# Sulfonamides (Sulfa drugs)

## Physicochemical properties of sulfa drugs

2- Amphoteric characters: [with acidic & basic characters] React as acid & base




The deprotonated form (in -OH medium) is more stable due to resonance stabilization

So, in when we make urine alkaline, we increase solubility [increase ionized form]

# Sulfonamides (Sulfa drugs)

## Synthesis of sulfonamides




## 2- Solubility of sulfa drugs

All sulfonamides are **insoluble in water** except the sodium salts, on the other hand all sulfonamides are **soluble in alkali** except sulfaguanidine, while all sulfonamides are soluble in acids.

# Sulfonamides (Sulfa drugs)

## Metabolism:

- By N4-acetylation: sulfonamides excreted as it's + N4-acetate + glucuronide [both are inactive]
- N4-acetate is less water soluble than parent drug, which lead to increase tendency of crystalluria



**Crystallurea:** precipitation of sulfonamide (has low water solubility) which may cause kidney damage

# Sulfonamides (Sulfa drugs)

## Crystallurea & PKa

- According to the following equation:

$$pK_a \text{ drug} = pH \text{ urine} + \log \frac{\text{Unionized form of the drug}}{\text{Ionized form of the drug}}$$

- ❖ If pH of urine = pKa of drug  $\rightarrow$  ionized/unionized = 1
- ❖ If pKa of drug > pH of urine  $\rightarrow$  unionized/ionized > 1  $\downarrow$  solubility
- ❖ If pKa of drug < pH of urine  $\rightarrow$  unionized/ionized < 1  $\uparrow$  solubility

# Sulfonamides (Sulfa drugs)

## Crystalluria & PKa

- According to the following equation:

$$pK_a_{\text{drug}} = \text{pH}_{\text{urine}} + \log \frac{\text{Unionized form of the drug}}{\text{Ionized form of the drug}}$$

- pH of urine is about 6 & pKa of sulfanilamide is 10.4 → so present in urine in unionized form → ↓ solubility → crystalluria & bleeding.

# Sulfonamides (Sulfa drugs)

## Crystallurea & PKa

### To solve problem of crystalluria:

- ❖ 1. Drinking large amount of water → ↑ urine flow by ↑ rate of glomerular filtration.
- ❖ 2. Combination therapy [ triple therapy ] : using mixed sulphonamides [ 3 sulpha drugs: Sulfadiazine + Sulfamerazine + Sulfamethazine ] → only 1/3 of the amount of each drug is used giving the same bacterial action but each one is present in amount less than its solubility product → no precipitation.
- ❖ 3. ↑ pH of urine by alkalinization [ using NaHCO<sub>3</sub> ]
- ❖ 4. ↓ pKa of drug by N1-substitution with electron-withdrawing group [ as heterocycle or acyl group ]

# Sulfonamides (Sulfa drugs)

## Crystalluria & PKa

### Question

if pka of sulfisoxazole is 5, determine its risk of crystalluria.

$$5 = 7 + \log \frac{\text{Unionized}}{\text{Ionized}}$$

$$\log \frac{\text{Unionized}}{\text{Ionized}} = -2 \quad \rightarrow \quad \frac{\text{Unionized}}{\text{Ionized}} = \frac{1}{100}$$


- ❖ So, it's present mainly in ionized form → more soluble → risk of crystaluria.

# Sulfonamides (Sulfa drugs)

## Assay of sulfonamide:

### [1] Methods depends on aromatic amino group [ N4 ] : Diazotization

1. Dissolve in dil.HCl & titrate  $\neq$  M/10 NaNO<sub>2</sub>  $\rightarrow$  diazonium salt.
2. E.p. is determined by ;
  - KI/starch as external indicator.
  - Potentiometrically.
  - Colorimetrically  $\rightarrow$  by coupling diazonium salt with  $\beta$ -naphthol in NaOH  $\rightarrow$  colored compound.




# Sulfonamides (Sulfa drugs)

## Assay of sulfonamide:

### [2] Methods depend on acidity of sulphonamides [ -SO<sub>2</sub>NH<sub>2</sub> ]

#### Sulfa drugs

[a] Non-aqueous titration	[b] Argentometric method [ Back titration]
<ul style="list-style-type: none"><li>As they are weak acids → dissolve in pyridine or DMF [basic solvent] &amp; titrate ≠ NaOCH<sub>3</sub>.</li><li>E.p. determined using thymol blue as indicator.</li></ul>	<ul style="list-style-type: none"><li>Add known xss of std. AgNO<sub>3</sub> in NaOH → insol. Ag Salt + equivalent amount of HNO<sub>3</sub>.</li><li>Ag salt is filtered out.</li><li>Either back titration of xss unreacted AgNO<sub>3</sub> in Filtrate ≠ NH<sub>4</sub>SCN &amp; ferric alum indicator [Volhard]</li></ul>




# Sulfonamides (Sulfa drugs)

## Assay of sulfonamide:

### [3] Bromometric method

1. Add known xss of standard  $\text{Br}_2$  solution in HCl  $\rightarrow$  bromination of sulphonamides.
2. xss  $\text{Br}_2$  determined by adding KI  $\rightarrow$   $\text{I}_2$   $\rightarrow$  titrated  $\neq$  std  $\text{Na}_2\text{S}_2\text{O}_3$

e.g. Sulfadiazine



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

**SYSTEMIC SULFONAMIDES  
[ORAL / ABSORBABLE]**

**TOPICAL SULFONAMIDES  
[SKIN / EYE]**

**INTESTINAL SULFONAMIDES  
[ORAL / NON-ABSORBABLE]**

### [i] Systemic Sulfoanmides

Used in treatment of systemic infections.

Classified according to rate of excretion [ $t_{1/2}$ ] into:

SHORT ACTING	MEDIUM ACTING	LONG ACTING
Taken every 6 hrs	Taken every 8-12 hrs	Taken every 24 hrs
$t_{1/2} < 10$ hrs	$t_{1/2} = 10-24$ hrs	With slow excretion rate

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

**SYSTEMIC SULFONAMIDES  
[ORAL / ABSORBABLE]**

**TOPICAL SULFONAMIDES  
[SKIN / EYE]**

**INTESTINAL SULFONAMIDES  
[ORAL / NON-ABSORBABLE]**

### [i] Systemic Sulfoanmides

**N<sup>1</sup>-ACYL DERIVATIVE**

**N<sup>1</sup>- HETEROATOMIC  
DERIVATIVE**

**PYRIMIDINE DERIVATIVES**

**ISOXAZOLE DERIVATIVES**

**PYRIDAZINE DERIVATIVES**


**THIADIAZOLE DERIVATIVES**



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [1] N1-Acyl Derivatives



N-[(4-aminophenyl) sulfonyl ] acetamide  
OR [N<sup>1</sup>-acetyl sulphanilamide]

- Water soluble, its solution with pKa 5.4 [acidic] → ↓↓ risk of crystalluria.
- Its Na salt is less alkaline than Na salts of other sulfonamides → non-irritant to mucous membrane ↗ used as eye drops till 30 % concentration.
- Can be used for urinary tract infection [why?] → it's highly soluble with t<sub>1/2</sub> = 7 hrs [rapid excretion]

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative

[ii] Pyridazine Derivative


[iii] Isoxazole Derivative

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [i] Pyrimidine Derivative (short acting)




**Sulfamethazine**

$t_{1/2} = 7 \text{ hrs} / \text{pka} = 7.2$

More water soluble > sulfadiazine & sulfamerazine in acidic urine [pH=5.5], but lower activity in vitro & in vivo.  
Used in combination sulfa [Tri-sulfapyrimidine therapy]

#### $N^1(4,6\text{-dimethyl- 2- pyrimidinyl})\text{ Sulphanilamide}$



**Sulfisomidine**

$t_{1/2} = 7.5 \text{ hrs}$

The most water soluble of pyrimidine derivatives  $\rightarrow \downarrow\downarrow$  tendency of crystalluria.

#### $N^1(2,6\text{-dimethyl- 4- pyrimidinyl})\text{ Sulphanilamide}$

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative (moderate or intermediate acting)

$t_{1/2} = 17$  hrs /  $pKa = 6.3$

Broad spectrum, the drug of choice in UTI.


$NaHCO_3$  is co-given [why ?]

Uses:

Na salt as 5 % solution(IV) : In Meningitis [penetrate into CSF].


Ag salt : topically in burns.

Sulfadiazine



$N^1(2-$  pyrimidinyl ) Sulphanilamide

Sulfamerazine



$t_{1/2} = 27$  hrs

Similar properties to sulfadiazine, but:

With more water solubility.

More absorbable.

Less excretion rate.

Higher blood level can be obtained with a similar dose.

$N^1(4$ -methyl-2- pyrimidinyl ) Sulphanilamide


# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides


### [2] N1-Heteroatomic Derivatives

[i] Pyrimidine Derivative (long acting)

Sulfameter



Sulfadimethoxine



N<sup>1</sup>(5-methoxy -2- pyrimidinyl)

Sulphanilamide

N<sup>1</sup>(2,6-dimethoxy-4- pyrimidinyl)

Sulphanilamide

Long duration of action due to presence of OCH<sub>3</sub> :

↑ plasma protein binding.

Drug-Plasma protein complex is too large to pass through kidney glomerular membrane  
→ ↓ excretion → long duration.

This binding also ↓ free form of drug → ↓ metabolism → longer duration.

As a result of ↓ excretion → may cause hypersensitivity upon accumulation.

t<sub>1/2</sub> of Sulfameter is 37-48 hrs & for Sulfadimethoxine is 40 hrs.

sulfameter with bitter taste → not used in liquid preparations → make N<sup>1</sup>-acetyl derivative [Prodrug].

# Sulfonamides (Sulfa drugs)


# Classification of Sulfonamides

## [2] N1-Heteroatomic Derivatives

## [i] Pyrimidine Derivative

## Synthesis of Pyrimidine derivatives:

## Synthesis of Sulfadiazine



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [i] Pyrimidine Derivative

##### Synthesis of Pyrimidine derivatives:

##### Synthesis of Sulfamerazine



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [i] Pyrimidine Derivative

##### Synthesis of Pyrimidine derivatives:

##### Synthesis of Sulfamethazine



# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

#### [ii] Pyridazine Derivative

##### [ii] Pyridazine Derivative


###### Sulfachloropyridazine



N<sup>1</sup>(6-chloro-3-pyridazinyl) Sulphanilamide


- $t_{1/2} = 8$  hrs  $\rightarrow$  short acting.
- Used in treatment of urinary tract infections.

###### Sulfamethoxypyridazine



N<sup>1</sup>(6-methoxy-3-pyridazinyl) Sulphanilamide

###### Sulfamethoxypyridazine acetyl



N<sup>1</sup>-acetyl-N<sup>1</sup>(6-methoxy-3-pyridazinyl) Sulphanilamide

- $t_{1/2} = 37$  hrs  $\rightarrow$  long acting [why?] , due to presence of methoxy group.
- With bitter taste.

- PRODRUG for sulfamethoxypyridazine  $\rightarrow$   $\downarrow$  bitter taste  $\rightarrow$  used for pediatrics.
- Inactive in vitro  $\rightarrow$  activated by deacetylation in intestine.


# Sulfonamides (Sulfa drugs)



## Classification of Sulfonamides

### [2] N1-Heteroatomic Derivatives

[iii] Isoxazole Derivative

[iii] Isoxazole Derivative

Sulfamethoxazole	
 <p><u>N<sup>1</sup>(5-methyl-3-isoxazolyl) Sulphanilamide</u></p>	<ul style="list-style-type: none"><li>• <math>t_{1/2} = 11</math> hrs <math>\rightarrow</math> short acting.</li><li>• <u>Not rapidly absorbed</u> as sulfisoxazole <math>\rightarrow</math> its peak blood level is only about 50 %.</li></ul>

Sulfaisoxazole	Sulfaisoxazole acetyl
 <p><u>N<sup>1</sup>(3,4-dimethyl-5-isoxazolyl) Sulphanilamide</u></p> <ul style="list-style-type: none"><li>• <math>t_{1/2} = 6</math> hrs <math>\rightarrow</math> short acting.</li><li>• Rapidly absorbed.</li><li>• <u>Highly water soluble</u> <math>\rightarrow</math> no need for using alkalinizing agent with it.</li><li>• With <u>bitter taste</u>.</li></ul>	 <p><u>N<sup>1</sup>-acetyl-N<sup>1</sup>(3,4-dimethyl-5-isoxazolyl) Sulphanilamide</u></p> <ul style="list-style-type: none"><li>• <u>PRODRUG</u> for sulfaisoxazole <math>\rightarrow</math> <math>\downarrow</math> bitter taste <math>\rightarrow</math> used for liquid oral preparations.</li><li>• Inactive in vitro <math>\rightarrow</math> activated by deacetylation in intestine.</li><li>• Less soluble than sulfisoxazole.</li></ul>


# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] topical Sulfoanmides

Sulfacetamide :

#### [1] N<sup>1</sup>-Acyl Derivatives

Sulfacetamide
 <p>N-[<u>(4-aminophenyl) sulfonyl</u>] acetamide OR [N<sup>1</sup>-acetyl sulphanilamide]</p>

- Water soluble, its solution with pka 5.4 [acidic] → ↓↓ risk of crystalluria.
- Its Na salt is less alkaline than Na salts of other sulfonamides → non-irritant to mucous membrane → used as eye drops till 30 % concentration.
- Can be used for urinary tract infection [why?] → it's highly soluble with  $t_{1/2} = 7$  hrs [rapid excretion]

# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [2] topical Sulfoanmides

Sulfadiazine Silver [Silvadene]

Mafenide acetate

#### Sulfadiazine Silver [Silvadene]




- Applied in water-miscible cream [**Dermazine®**] → active topically ≠ *Pseudomonas* species → used in **burn therapy** [that *Pseudomonas* is responsible for failure of therapy]
- Slightly soluble, Not penetrate cell wall but act on external cell structures.
- Prepared by mixing equimolar amount of AgNO<sub>3</sub> & Na sulfadiazine [both dissolved in water].

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] topical Sulfoanmides

Mafenide acetate	
<p></p> <p><b>acetate salt is formed with basic N not with acidic N</b></p>	<ul style="list-style-type: none"><li>• <b><u>NOT TRUE SULFONAMIDE COMPOUND</u></b> <b><u>[NOT TYPICAL SULFONAMIDE]</u></b></li><li>• <u>Not inhibited by PABA</u> [its M.O.A. involve different <u>unknown mechanism</u> than true sulfonamides].</li><li>• <u>Not affected by pH</u>.</li><li>• Effective ≠ <i>Clostridium welchii</i> in topical use for <u>infected wounds</u>.</li><li>• Not effective orally.</li><li>• Used alone or with antibiotics in ttt of slow healing infected wounds.</li><li>• If used in large quantities → <u>metabolic acidosis</u>. So, a series of new organic salts was prepared.</li><li>• The <u>acetate derivative</u> in ointment base is the most efficient.</li></ul>


# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [2] topical Sulfoanmides

Mafenide metabolism

#### METABOLISM:



Both Mafenide & its metabolite [P-carboxy benzene sulfonamide] cause INHIBITION OF CARBONIC ANHYDRASE ENZYME → METABOLIC ACIDOSIS.

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides


### [3] non-absorbable Sulfoanmides

[i] Topical Sulfonamides : Sulfadiazine Ag & Mafenide acetate.

#### [ii] Intestinal Sulfonamides

- They are **PRODRUGS** designed to be poorly absorbed, in large intestine → cleavaged → free sulfonamide "active".
- Used in treatment of intestinal infections, ulcerative colitis & reduction of bowel flora.

sulfaguanidine



- **Guanidine is a basic moiety that cause:**
  1. ↓ absorption.
  2. ↓ lipid solubility.
- Poorly absorbed [with additional basic group] → not absorbed from GIT → high local concentration.







N<sup>1</sup>-amidino sulfanilamide

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [3] non-absorbable Sulfoanmides

#### Sulfa drugs



<u><math>N^4</math>-substituted Sulfonamides</u> [Acylation with Dicarboxylic acids "Succinic & Phthalic acids"]		
<u>Succinyl sulphathiazole</u>  <chem>CS(=O)(=O)Nc1ccsc1Nc2ccccc2S(=O)(=O)N</chem>	<u>Phthalyl sulphathiazole</u>  <chem>CS(=O)(=O)Nc1ccsc1Nc2ccccc2C(=O)C(=O)O</chem>	<u>Phthalyl sulphacetamide</u>  <chem>CS(=O)(=O)Nc1ccsc1Nc2ccccc2C(=O)C(=O)OCC</chem>
<u>2-(<math>N^4</math>-succinyl sulfanilamide) thiazole</u>  <chem>CS(=O)(=O)Nc1ccsc1Nc2ccccc2C(=O)C(=O)CH2CH2COOH</chem>	<u>2-(<math>N^4</math>-phthalyl sulfanilamide) thiazole</u>  <chem>CS(=O)(=O)Nc1ccsc1Nc2ccccc2C(=O)C(=O)COOH</chem>	<u><math>N^4</math>-acetyl-<math>N^4</math>-phthalyl sulfanilamide</u>  <chem>CS(=O)(=O)Nc1ccsc1Nc2ccccc2C(=O)C(=O)OCC(=O)C</chem>
They have additional acidic group → poorly absorbed from GIT. They are <b>PRODRUGS</b> → activated in vivo by slow hydrolysis giving ↑ local concentration. With <u>little use now</u>		

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### [3] non-absorbable Sulfoanmides

#### Sulfa drugs


sulfasalazine	
 <p><u>5-[4-(2-pyridyl sulfamoyl) phenyl azo]</u> <u>salicylic acid</u></p>	<p><b>ONLY SULFAPYRIDINE DERIVATIVE.</b> <b>ONLY USED IN ULCERATIVE COLITIS.</b></p> <ul style="list-style-type: none"><li>Water insoluble, broken in body giving: <u>m-amino saicylic acid</u> [anti-inflammatory] + <u>Sulfapyridine</u> [anti-bacterial] → so, it acts as carrier for <u>5-amino salicylic acid</u> → <u>USED IN ULCERATIVE COLITIS</u> it</li></ul> <div style="border: 1px solid black; padding: 10px; text-align: center;"><p><b>5-amino salicylic acid</b> + <b>sulfapyridine</b></p></div>

# Sulfonamides (Sulfa drugs)


## Classification of Sulfonamides

### [3] non-absorbable Sulfoanmides

#### Synthesis:



It occurs by electrophilic substitution reaction at P-position of salicylic acid [why?]



# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

### Adverse effects of sulfonamides therapy:

Gastrointestinal distress.

Hemolytic anemia.

Hepatitis.

Stevens-Johnson Syndrome [sever skin eruption].


**Crystalluria.**

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

Combination of sulfonamides with  
Dihydrofolate Reductase Inhibitor

### Trimethoprim




It's potent anti-bacterial by inhibition of DHFR enzyme → → stop bacterial growth.  
Selective in action → 100.000 times more active ≠ bacterial DHFR relative to  
mammalian DHFR. [used for UTI]  
Combined with Sulfamethoxazole as both have the same pharmacokinetic properties [ $t_{1/2} = \text{hrs}$  like that of sulfamethoxazole] → excreted at about the same time.[important condition for combination between two drugs]

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

Combination of sulfonamides with  
Dihydrofolate Reductase Inhibitor

M.O.A of combination:




Remember ☺ : ↓ THFA synthesis → ↓ purine & pyrimidine bases synthesis → ↓ DNA synthesis → stop growth of bacteria.

# Sulfonamides (Sulfa drugs)

## Classification of Sulfonamides

Combination of sulfonamides with  
Dihydrofolate Reductase Inhibitor

### Trimethoprim



Trimethoprim combined with Sulfamethoxazole [Sutrim®][Septazole®][Septrin®]

#### Advantages of this combination:

1. Synergism due to sequential blockage.
2. Avoid development of resistance [if use sulfamethoxazole alone].
3. Broader spectrum of activity.
4. Bactericidal instead of Bacteriostatic.

# Sulfonamides (Sulfa drugs)

## Important notes

### Sulfonamides

- Prototype is Sulfanilamide [from prontosil prodrug].
- Bacteriostatic NOT bactericidal
- Act by competitive inhibition of dihydropteroate synthetase enzyme → inhibit folic acid synthesis → inhibit DNA synthesis.
- Structurally similar to PABA → as structure more similar to PABA, it becomes more active.
- Crystalluria → sulpha & acetyl metabolites are sparingly soluble in water.
- ↑ pH of urine or ↓ pKa of drug → ↓ risk of crystalluria.
- ↓ pKa → ↑ solubility → ↓ risk of crystalluria → UTI.
- Assay: depend on acidity [non-aqueous/argentometry], basicity [diazotization] / bromometry.
- Sulfacetamide Na salt is less alkaline than Na salts of other sulfa drugs → due to higher acidity → eye drops.
- ↑ methyl groups on pyrimidine → ↑ solubility.
- Methoxy group → bind to plasma proteins → long duration.
- To overcome bitter taste of sulfa drugs → acetyl prodrug on N<sup>1</sup>.
- Ag sulfadiazine [act on external cell structure] & mafénide acetate [NOT true sulfa] → used topically for burns.
- Additional basic or acidic moiety → intestinal sulfa.
- Sulfasalazine → only pyridine derivative → only used in ulcerative colitis.
- Best combination → Sulfamethoxazole [DHPS inhibitor] + Trimethoprim [DHFR inhibitor]

# Sulfonamides (Sulfa drugs)

## Sample questions

### Questions

#### ① [a] Complete the following :

1. Compound A has generic name: -----

Its chemical name is -----

It's used for ----- while its silver salt is used for -----

It can be assayed by -----

How can you synthesize compound A:

2. Sulpha triple therapy has the advantages of -----

3. Sulfonamides are metabolized mainly by -----



4. Sulfonamides are made more soluble in urine by -----, -----, ----- or -----

5. Duration of action of ----- [sulfa drug] is long due to -----

6. Sulfacetamide is used for ----- due to -----

7. Sutrim is a combination of ----- & ----- Its advantages are -----, -----, -----, ----- & -----

8. In the bromometric assay for determination of the compound B, it consumes ----- molecules of Bromine.



# Sulfonamides (Sulfa drugs)


## Sample questions

9. Compound C is more water soluble than sulfadiazine.

It has the advantage -----

-----

T      F



10. N<sup>4</sup>-acylaiton with dicarboxylic acid yields a sulfonamide used in -----

11. The following mechanisms may be seen in species resistant to sulfonamide therapy:

1. -----

2. -----

3. -----

12. The mode of action of sulfonamides involves -----

13. Sulphonamides are assayed by :

[a] -----




[b] -----

[c] -----

14. The ----- salt of sulfadiazine is used topically while ----- salt is used I.V.

15. The basic intestinal sulfonamide is ----- while the acidic intestinal sulfonamides are -----, -----, -----

7. To design a long acting sulfonamide, the condensation step in preparation of sulpha can be done with:



# Sulfonamides (Sulfa drugs)







## Sample questions

**[b]** In determination of activity of some sulfa drugs, the following data were reported:

Drug	A) Sulfanilamide	B) Sulfacetamide	C) Sulfamethazine
pKa	10.4	7.2	5.4

- Determine which one with the lowest risk of crystalluria [illustrate your answer with calculation].
- C is preferred over A for urinary tract infection.  T  F
- A is the best one used as eye drops.  T  F
- Starting from A, how can you synthesize B & C.

[c]




Compound	Active / Inactive	The reason
1		
2		
3		
4		
5		
6		

# Sulfonamides (Sulfa drugs)

## Sample questions

**[a] Modify the drawn structure into two derivatives acting locally :**



Drug A : \_\_\_\_\_  
used as \_\_\_\_\_  
because \_\_\_\_\_  
\_\_\_\_\_  
Chemical name : \_\_\_\_\_  
\_\_\_\_\_

Drug B : \_\_\_\_\_  
used for \_\_\_\_\_  
because \_\_\_\_\_  
\_\_\_\_\_  
Chemical name : \_\_\_\_\_  
\_\_\_\_\_


**[b] Give a direct assays of sulfadiazine & another back titration.**

**[c] What's the effect of the following modifications on 4-aminobenzene sulfonamide?**

- [a] Replacing amino group by methyl amino.
- [b] Replacing amino group by amino methyl.
- [c] Addition of amidino group to N<sup>1</sup>.
- [d] Action of acetyltransferase.
- [e] Increase pH of urine from 5 to 7.
- [f] Substitution of acidic center with 4,6-dimethoxy-2-pyrimidinyl.

**[d] A new product with the drawn structure was designed, it's expected to be active in: [Rationalize your answer]**

- [a] Intestinal infections & ulcerative colitis.
- [b] Intestinal infections.
- [c] Ulcerative colitis.
- [d] Non of the above.



The end

THANK YOU  
for your  
ATTENTION